Biotech Values

[genisi]

The lead-in phase can also assist in patient selection:
patients with low baseline viral load and RVR, who do not require the addition of a protease inhibitor (these pts will most likely achieve SVR anyway), and non responders to PEG-IFN/RBV who might receive functional monotherapy by addition of a protease inhibitor.